プロマクタの世界市場レポート2025

プロマクタ市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.4％で56億9,000万米ドルに成長します。予測期間における成長の原動力は、研究開発の増加、政府による取り組みの拡大、世界の老人人口の増加、患者教育への注力の強化、患者支援プログラムの拡大、ヘルスケアインフラの成長、可処分所得の増加などです。主な動向としては、ジェネリック医薬品やバイオシミラーの開発、患者中心の医療へのシフト、バイオテクノロジーや医薬品の主な発展、遠隔医療や遠隔モニタリングの採用、進行中の臨床試験や研究開発などが挙げられます。

再生不良性貧血の有病率の増加は、今後数年間におけるプロマクタ市場の拡大を促進すると予想されます。再生不良性貧血は、骨髄が十分な血球を産生できず、疲労、感染症、出血リスクの上昇を引き起こすまれな疾患です。再生不良性貧血の蔓延には、有毒化学物質への曝露、特定の薬剤、ウイルス感染、自己免疫疾患、遺伝的素因など様々な要因が関与しています。プロマクタは、骨髄幹細胞を刺激して血液細胞を生成させ、血小板数、赤血球数、好中球数を増加させます。これにより、輸血の必要性が減少し、再生不良性貧血の患者における出血や感染症のリスクが低下します。例えば、2024年4月、白血病と造血幹細胞移植を専門とする英国の慈善団体アンソニー・ノーランは、英国では毎年約100人から150人が再生不良性貧血と診断されると報告しました。その結果、この疾患の有病率が上昇し、プロマクタ市場の成長に拍車をかけています。

プロマクタ市場の拡大は、ヘルスケア支出の増加によっても促進されています。ヘルスケア支出には、公衆および個人の健康の維持・改善を目的とした医療サービス、治療、インフラの総コストが含まれます。ヘルスケア支出の増加には、高齢化、医療技術の進歩、健康保険の適用範囲拡大など、いくつかの要因が寄与しています。ヘルスケア支出の増加は、血小板減少症やその他の血液疾患に対する革新的な治療法への患者のアクセスを高めると同時に、診断能力を向上させ、早期発見を可能にし、プロマクタの採用を促進します。例えば、2023年12月、米国の連邦政府機関であるメディケア＆メディケイド・サービスセンターは、2022年の米国の医療費が4.1％増の4兆5,000億米ドルに達し、2021年の3.2％増から加速したと報告しました。このような医療支出の増加傾向は、プロマクタ市場の成長に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界プロマクタPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のプロマクタ市場：成長率分析
• 世界のプロマクタ市場の実績：規模と成長, 2019-2024
• 世界のプロマクタ市場の予測：規模と成長, 2024-2029, 2034F
• 世界プロマクタ総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のプロマクタ市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性免疫血小板減少症
• 重症再生不良性貧血
• C型肝炎関連血小板減少症
• その他の適応症
• 世界のプロマクタ市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 経口懸濁液
• 世界のプロマクタ市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のプロマクタ市場、食事管理の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ロレンツォのオイル
• オメガ3脂肪酸
• 脂肪酸サプリメント
• 世界のプロマクタ市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイド
• 抗酸化物質
• 抗炎症薬
• 世界のプロマクタ市場幹細胞療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 造血幹細胞移植（HSCT）
• 遺伝子治療

第7章 地域別・国別分析

• 世界のプロマクタ市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のプロマクタ市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• プロマクタ市場：競合情勢
• プロマクタ市場：企業プロファイル
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 世界の市場競合ベンチマーキングとダッシュボード

第32章 主要な合併と買収

第33章 最近の市場動向

第34章 市場の潜在力が高い国、セグメント、戦略

• プロマクタ市場2029：新たな機会を提供する国
• プロマクタ市場2029：新たな機会を提供するセグメント
• プロマクタ市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第35章 付録

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) designed to stimulate platelet production in patients with specific blood disorders. It is primarily prescribed for conditions where platelet production is insufficient, increasing the risk of bleeding. By boosting platelet levels, Promacta helps reduce bleeding risk in affected patients.

The primary indications for Promacta include chronic immune thrombocytopenia, severe aplastic anemia, hepatitis C-associated thrombocytopenia, and other related conditions. Chronic immune thrombocytopenia (ITP) is a persistent autoimmune disorder that leads to low platelet levels, resulting in excessive bleeding and requiring treatments to suppress immunity or enhance platelet production. Promacta is available in various dosage forms, such as tablets and oral suspension, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The promacta market research report is one of a series of new reports from The Business Research Company that provides promacta market statistics, including the promacta industry global market size, regional shares, competitors with the promacta market share, detailed promacta market segments, market trends, and opportunities, and any further data you may need to thrive in the promacta industry. This promacta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The promacta market size has grown strongly in recent years. It will grow from $3.79 billion in 2024 to $4.12 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the increasing prevalence of immune thrombocytopenic purpura (ITP), a decline in platelet counts, a rising incidence of conditions such as aplastic anemia and immune thrombocytopenia, a growing emphasis on patient education, and an increase in healthcare expenditure.

The promacta market size is expected to see strong growth in the next few years. It will grow to $5.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The projected growth in the forecast period is driven by increased research and development, expanding governmental efforts, a rising global geriatric population, a stronger focus on patient education, the expansion of patient assistance programs, growing healthcare infrastructure, and higher disposable incomes. Key trends include the development of generic alternatives and biosimilars, a shift toward patient-centric care, advancements in biotechnology and pharmaceuticals, the adoption of telemedicine and remote monitoring, and ongoing clinical trials and research initiatives.

The growing prevalence of aplastic anemia is anticipated to drive the expansion of the promacta market in the coming years. Aplastic anemia is a rare condition where the bone marrow fails to produce enough blood cells, leading to fatigue, infections, and a heightened risk of bleeding. Various factors contribute to the prevalence of aplastic anemia, including exposure to toxic chemicals, certain medications, viral infections, autoimmune disorders, and genetic predisposition. Promacta aids in stimulating bone marrow stem cells to generate blood cells, thereby increasing platelet, red blood cell, and neutrophil counts. This reduces the need for transfusions and lowers the risk of bleeding and infections in individuals affected by aplastic anemia. For example, in April 2024, Anthony Nolan, a UK-based charity specializing in leukemia and hematopoietic stem cell transplantation, reported that approximately 100 to 150 individuals in the UK are diagnosed with aplastic anemia each year. As a result, the rising prevalence of this condition is fueling the growth of the promacta market.

The expansion of the promacta market is also being driven by increased healthcare expenditure. Healthcare expenditure encompasses the total cost of medical services, treatments, and infrastructure aimed at maintaining and improving public and individual health. Several factors contribute to rising healthcare expenditures, including an aging population, advancements in medical technology, and broader health insurance coverage. Increased healthcare spending enhances patient access to innovative treatments for thrombocytopenia and other blood disorders, while also improving diagnostic capabilities, enabling early detection, and promoting the adoption of promacta. For instance, in December 2023, the Centers for Medicare & Medicaid Services, a US-based federal agency, reported that US healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion, marking an acceleration from the 3.2% increase observed in 2021. This upward trend in healthcare expenditure is contributing to the growth of the promacta market.

The growing geriatric population is playing a significant role in the expansion of the promacta market. Individuals aged 65 and older often require specialized medical care to address age-related health concerns. The rise in the elderly population is attributed to increasing life expectancy, advancements in healthcare, declining birth rates, and improvements in medical treatments. Promacta benefits older adults by stimulating platelet production in those with blood disorders, reducing the risk of bleeding, enhancing immune function, and improving overall treatment outcomes. For example, in January 2024, the Population Reference Bureau, a Kenya-based nonprofit organization, projected that the number of Americans aged 65 and older would rise from 58 million in 2022 to 82 million by 2050. Consequently, the expanding geriatric population is a key factor driving the growth of the promacta market.

The key player in the promacta market is Novartis AG.

North America was the largest region in the promacta market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in promacta report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the promacta market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The promacta market consists of sales of extended-release tablets and powder for suspension. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Promacta Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on promacta market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for promacta ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The promacta market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Indication: Chronic Immune Thrombocytopenia; Severe Aplastic Anemia; Hepatitis C-associated Thrombocytopenia; Other Indications
• 2) By Dosage Form: Tablets; Oral Suspension
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Chronic Immune Thrombocytopenia (ITP): Primary Immune Thrombocytopenia; Secondary Immune Thrombocytopenia
• 2) By Severe Aplastic Anemia: Adult Severe Aplastic Anemia; Pediatric Severe Aplastic Anemia
• 3) By Hepatitis C-associated Thrombocytopenia: Genotype 1 Hepatitis C-associated Thrombocytopenia; Genotype 2 Hepatitis C-associated Thrombocytopenia; Genotype 3 Hepatitis C-associated Thrombocytopenia
• 4) By Other Indications: Myelodysplastic Syndromes (MDS); Bone Marrow Disorders; Radiation-Induced Thrombocytopenia
• Companies Mentioned: Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Promacta Market Characteristics

3. Promacta Market Trends And Strategies

4. Promacta Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Promacta Growth Analysis And Strategic Analysis Framework

• 5.1. Global Promacta PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Promacta Market Growth Rate Analysis
• 5.4. Global Promacta Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Promacta Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Promacta Total Addressable Market (TAM)

6. Promacta Market Segmentation

• 6.1. Global Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Immune Thrombocytopenia
• Severe Aplastic Anemia
• Hepatitis C-associated Thrombocytopenia
• Other Indications
• 6.2. Global Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Oral Suspension
• 6.3. Global Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.4. Global Promacta Market, Sub-Segmentation Of Dietary Management, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lorenzo's Oil
• Omega-3 Fatty Acids
• Fatty Acid Supplements
• 6.5. Global Promacta Market, Sub-Segmentation Of Medications, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Antioxidants
• Anti-inflammatory Drugs
• 6.6. Global Promacta Market, Sub-Segmentation Of Stem Cell Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hematopoietic Stem Cell Transplantation (HSCT)
• Gene Therapy

7. Promacta Market Regional And Country Analysis

• 7.1. Global Promacta Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Promacta Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Promacta Market

• 8.1. Asia-Pacific Promacta Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Promacta Market

• 9.1. China Promacta Market Overview
• 9.2. China Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Promacta Market

• 10.1. India Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Promacta Market

• 11.1. Japan Promacta Market Overview
• 11.2. Japan Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Promacta Market

• 12.1. Australia Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Promacta Market

• 13.1. Indonesia Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Promacta Market

• 14.1. South Korea Promacta Market Overview
• 14.2. South Korea Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Promacta Market

• 15.1. Western Europe Promacta Market Overview
• 15.2. Western Europe Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Promacta Market

• 16.1. UK Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Promacta Market

• 17.1. Germany Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Promacta Market

• 18.1. France Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Promacta Market

• 19.1. Italy Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Promacta Market

• 20.1. Spain Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Promacta Market

• 21.1. Eastern Europe Promacta Market Overview
• 21.2. Eastern Europe Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Promacta Market

• 22.1. Russia Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Promacta Market

• 23.1. North America Promacta Market Overview
• 23.2. North America Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Promacta Market

• 24.1. USA Promacta Market Overview
• 24.2. USA Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Promacta Market

• 25.1. Canada Promacta Market Overview
• 25.2. Canada Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Promacta Market

• 26.1. South America Promacta Market Overview
• 26.2. South America Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Promacta Market

• 27.1. Brazil Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Promacta Market

• 28.1. Middle East Promacta Market Overview
• 28.2. Middle East Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Promacta Market

• 29.1. Africa Promacta Market Overview
• 29.2. Africa Promacta Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Promacta Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Promacta Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Promacta Market Competitive Landscape And Company Profiles

• 30.1. Promacta Market Competitive Landscape
• 30.2. Promacta Market Company Profiles
  • 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Global Promacta Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Promacta Market

33. Recent Developments In The Promacta Market

34. Promacta Market High Potential Countries, Segments and Strategies

• 34.1 Promacta Market In 2029 - Countries Offering Most New Opportunities
• 34.2 Promacta Market In 2029 - Segments Offering Most New Opportunities
• 34.3 Promacta Market In 2029 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer